Our clinical pipeline consists of novel, non-opioid pain therapies aimed at new or emerging pharmacological targets selectively interrupting pain transmission pathways to more effectively treat moderate to severe chronic pain without risks of dependence or abuse.
We are studying our therapies in companion animals with the same naturally-occurring, pain-causing disease conditions that are common to both humans and animals. By validating the safety and therapeutic effect of our treatments in both humans and animals, we are able to work on parallel tracks to develop human and veterinary treatments.
Capsaicin is a naturally-occurring compound found in chili peppers that has been safely used as a spice and medicine for centuries. Capsaicin has been used as an over-the-counter topical analgesic for decades, to provide temporary relief from mild-to-moderate pain associated with common conditions including osteoarthritis and neuropathic pain.
Our STRATI™ technology (Synthetic TRans cApsaicin ulTra-pure Injection), is a selective, highly potent, ultra-pure, synthetic form of trans-capsaicin that is injected directly into the site of pain. It harnesses the natural analgesic power of capsaicin to develop a proprietary injectable therapy designed to provide fast-acting, long-lasting and targeted pain relief.
Our lead therapeutic candidate, CNTX-4975, is based on our STRATI™ technology. CNTX-4975 is being evaluated for the treatment of osteoarthritis pain of the knee in humans and canines, as well as in patients with Morton’s neuroma, a rare, painful foot condition.
STRATI™ works by targeting the TRPV1 receptor that selectively inactivates the local pain fibers transmitting pain signals to the brain, potentially providing relief that can last for up to six months, until the local pain fibers regenerate. Through its targeted delivery and highly selective method of action, CNTX-4975 manages pain without disrupting other nerve functions.
CNTX-4975 was granted Fast Track designation for the treatment of pain associated with knee osteoarthritis from the U.S. FDA in January 2018.
In February 2018, the first patient was dosed in the company’s Phase 3 VICTORY-1 clinical trial of CNTX-4975, a randomized, double-blind, placebo-controlled, 52-week study to evaluate the safety and efficacy of a single injection of CNTX-4975 in people with chronic, moderate to severe OA knee pain.
Positive results from our TRIUMPH Phase 2b trial have been recently presented at several leading medical conferences. TRIUMPH was a randomized, double-blind, placebo-controlled, multicenter clinical trial, in which patients with chronic moderate to severe pain due to knee osteoarthritis were given a single intra-articular (into the joint) injection of CNTX-4975. The trial showed that patients receiving CNTX-4975 experienced a rapid and highly statistically significant reduction in pain that occurred within days and lasted at least six months. Twenty-two percent of patients treated with CNTX-4975 achieved a 90 percent or greater reduction in pain and 67 percent of patients achieved 50 percent or greater reduction in pain.
CNTX-4975 was granted Orphan Drug and Fast Track designations for Morton’s neuroma by the U.S. FDA.
Positive results of the Phase 2b study in patients with Morton’s neuroma pain have also been recently presented at leading medical conferences. In the randomized, double-blind, placebo-controlled, multicenter Phase 2b STRIDE clinical trial, patients were given a single local injection of CNTX-4975 in the area of their neuroma. Treatment with CNTX-4975 produced a rapid and statistically significant in reduction in pain that lasted until the end of the 12 week trial in a post hoc analysis.
How CNTX-4975 Works
TRPV1 expressing neurons after exposure to capsaicin.
Source: Man-Kyo Chung UMD 2015
CNTX-2022 is a proprietary, high concentration (40%) topical gel formulation of lidocaine. It has the potential to be used to address pain across a broad range of indications including superficial musculoskeletal pain, neuropathic pain and dermatologic pain/discomfort.
BUILDING A PAIN POWERHOUSE
Through strategic in-licensing, we acquired three promising analgesics from Boehringer Ingelheim’s research and discovery portfolio, each one with a promising, unique profile for the treatment of chronic pain.
Recent studies have shown a close link between chronic pain and the immune system. CNTX-6970 capitalizes on this connection by taking a novel neuro-immune approach. The compound has a dual effect: stopping immune cells from releasing the potent cytokine CCL2 and stopping CCL2 from stimulating pain fibers to send pain signals. Based on our extensive big data analytics and research, CNTX-6970 is predicted to be well suited to treat chronic painful inflammatory conditions such as osteoarthritis. CNTX-6970 is in development to treat inflammatory pain and data to date have shown that CNTX-6970 is safe and well tolerated and has demonstrated pharmacologic activity evidenced by target engagement.
It is 20,000 times more selective for the CB2 receptor than the CB1, and thereby able to achieve pain relief without psychotropic and other side effects seen with less selective agonists. Based on our big data analytics and research, it looks most promising in neuropathic pain models and is well suited to treat chronic painful conditions such as diabetic neuropathic pain.
CNTX-0290 works by activating the SSTR4 receptor, which functions as a master control switch to turn down the activity of several other pain receptors, such as specific calcium channels, potassium channels and TRPV1 and TRPA1 channels, thereby reducing the transmission of pain signals. CNTX-0290 has shown activity in every chronic pain model it has been tested in to date. Based on our big data analytics, we believe it has promise in treating a wide variety of chronic pain conditions and could be especially valuable for mixed pain, such as chronic back pain.